Setting new standards in information exchange for the pharmaceutical and biotech industry
Immunotherapy pioneers awarded Nobel Prize
October 1, 2018
Drs James P Allison, of MD Anderson Cancer Center and Tasuku Honjo, Kyoto University, were awarded the Nobel prize for medicine for their work in immunotherapy. As mentioned in the Guardian, “The scientists’ groundbreaking work on the immune system has paved the way for a new class of cancer drugs that are already dramatically changing outcomes for patients. It is the first time the development of a cancer therapy has been recognized with a Nobel prize.” This prize is awarded at an exciting time for cancer research after breakthroughs in immune system therapies had evaded scientists for many years. The Nobel prize committee mentioned that “For more than 100 years scientists attempted to engage the immune system in the fight against cancer. Until the seminal discoveries by the two laureates, progress into clinical development was modest. Checkpoint therapy has now revolutionized cancer treatment and has fundamentally changed the way we view how cancer can be managed.” Many are thrilled with the award, which highlights an important and fast growing treatment method which could, in turn, save millions of lives in years to come. Read more here.
The Immuno-Oncology 360˚ event takes place February 6-8, 2019 in New York City where representatives from the National Cancer Institute, MD Anderson Cancer Center, among other research institutions, pharmaceutical companies, and investment firms will report on the latest advancements on the progress of IO followed by networking and partnering meetings. For more information about IO 360, click here.